The conference will provide attendees with an opportunity to learn about the key developments impacting the future of pharmaceutical pricing and reimbursement, including:
The increasing importance of generating, collecting and analyzing reimbursement evidence early in product development and identifying points of differentiation of a product versus existing standards of care
The impact of Health Technology Assessments (HTAs) on both private and public payer reimbursement decisions
Coverage with Evidence Development (CED) and performance-based risk-sharing agreements, based on long-term outcomes
The role of comparative effectiveness in future clinical trials and reimbursement decisions
Value-base pricing, which requires companies to back up reimbursement claims with strong evidence that products are a good use of money available
Alternative and shared risk pricing schemes
The increasing importance of generating, collecting and analyzing reimbursement evidence early in product development and identifying points of differentiation of a product versus existing standards of care
The impact of Health Technology Assessments (HTAs) on both private and public payer reimbursement decisions
Coverage with Evidence Development (CED) and performance-based risk-sharing agreements, based on long-term outcomes
The role of comparative effectiveness in future clinical trials and reimbursement decisions
Value-base pricing, which requires companies to back up reimbursement claims with strong evidence that products are a good use of money available
Alternative and shared risk pricing schemes
